Eli Lilly & Co (0Q1G) Share Forecast & Price Target

Compare

26 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0Q1G Analyst Ratings

Strong Buy

18 Buy

3 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0Q1G Stock 12 Month Forecast

Average Price Target

CHF791.13

▲(71.98% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is CHF791.13 with a high forecast of CHF1,008.18 and a low forecast of CHF564.58. The average price target represents a 71.98% change from the last price of CHF460.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"459":"CHF459","734":"CHF734","1009":"CHF1,009","596.5":"CHF596.5","871.5":"CHF871.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1008.1750875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF1.01K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":791.1270892623,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF791.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":564.578049,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF564.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[459,596.5,734,871.5,1009],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,460,502.1673144230769,544.3346288461538,586.5019432692308,628.6692576923077,670.8365721153846,713.0038865384615,755.1712009615385,797.3385153846154,839.5058298076923,881.6731442307693,923.8404586538461,966.0077730769231,{"y":1008.1750875,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,460,485.4713145586385,510.9426291172769,536.4139436759153,561.8852582345538,587.3565727931923,612.8278873518308,638.2992019104693,663.7705164691077,689.2418310277462,714.7131455863846,740.1844601450232,765.6557747036616,{"y":791.1270892623,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,460,468.0444653076923,476.0889306153846,484.13339592307693,492.1778612307692,500.2223265384615,508.2667918461538,516.3112571538461,524.3557224615384,532.4001877692308,540.444653076923,548.4891183846154,556.5335836923076,{"y":564.578049,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":540,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":540,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":460,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 78,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":460,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF1,008

Average Price TargetCHF791.13

Lowest Price TargetCHF564.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

UBS

CHF720.36→CHF869.26

Buy

88.97%

Upside

Reiterated

11/07/25

Eli Lilly price target raised to $1,080 from $895 at UBSEli Lilly price target raised to $1,080 from $895 at UBS

Geoff Meacham

Citi

CHF957.8→CHF1,006.09

Buy

118.72%

Upside

Reiterated

11/07/25

Eli Lilly price target raised to $1,250 from $1,190 at CitiEli Lilly price target raised to $1,250 from $1,190 at Citi

Terence Flynn

Morgan Stanley

CHF860.41→CHF877.31

Buy

90.72%

Upside

Reiterated

11/07/25

Eli Lilly price target raised to $1,090 from $1,069 at Morgan StanleyEli Lilly price target raised to $1,090 from $1,069 at Morgan Stanley

Tim Anderson

Bank of America Securities

CHF764.63

Buy

66.22%

Upside

Reiterated

11/06/25

Eli Lilly GLP-1 pricing deal 'probably a good tradeoff,' says BofAEli Lilly GLP-1 pricing deal 'probably a good tradeoff,' says BofA

Carter Gould

Cantor Fitzgerald

CHF792.8

Buy

72.35%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Remains a Buy on Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

CHF748.53→CHF885.36

Buy

92.47%

Upside

Reiterated

11/05/25

BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Chris Schott

J.P. Morgan

CHF845.12

Buy

83.72%

Upside

Reiterated

11/03/25

J.P. Morgan Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

CHF835.46

Buy

81.62%

Upside

Reiterated

10/31/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Akash Tewari

Jefferies

CHF728.41→CHF785.56

Buy

70.77%

Upside

Reiterated

10/31/25

Eli Lilly & Co (LLY) Gets a Buy from Jefferies

Veda Pharmyne

TR | OpenAI - 4o

CHF730.83→CHF767.85

Buy

66.92%

Upside

Reiterated

10/31/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

CHF885.36

Buy

92.47%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)

Steve Scala

TD Cowen

CHF772.68

Buy

67.97%

Upside

Reiterated

10/30/25

Eli Lilly & Co (LLY) Gets a Buy from TD Cowen

David Risinger

Leerink Partners

CHF575.49

Hold

25.11%

Upside

Reiterated

10/23/25

Leerink Partners Keeps Their Hold Rating on Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

CHF705.07→CHF707.49

Buy

53.80%

Upside

Reiterated

10/20/25

Eli Lilly & Co: Strategic Positioning and Clinical Advancements Drive Buy Rating

Seamus Fernandez

Guggenheim

CHF763.02

Buy

65.87%

Upside

Reiterated

10/15/25

Guggenheim Remains a Buy on Eli Lilly & Co (LLY)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

UBS

CHF720.36→CHF869.26

Buy

88.97%

Upside

Reiterated

11/07/25

Eli Lilly price target raised to $1,080 from $895 at UBSEli Lilly price target raised to $1,080 from $895 at UBS

Geoff Meacham

Citi

CHF957.8→CHF1,006.09

Buy

118.72%

Upside

Reiterated

11/07/25

Eli Lilly price target raised to $1,250 from $1,190 at CitiEli Lilly price target raised to $1,250 from $1,190 at Citi

Terence Flynn

Morgan Stanley

CHF860.41→CHF877.31

Buy

90.72%

Upside

Reiterated

11/07/25

Eli Lilly price target raised to $1,090 from $1,069 at Morgan StanleyEli Lilly price target raised to $1,090 from $1,069 at Morgan Stanley

Tim Anderson

Bank of America Securities

CHF764.63

Buy

66.22%

Upside

Reiterated

11/06/25

Eli Lilly GLP-1 pricing deal 'probably a good tradeoff,' says BofAEli Lilly GLP-1 pricing deal 'probably a good tradeoff,' says BofA

Carter Gould

Cantor Fitzgerald

CHF792.8

Buy

72.35%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Remains a Buy on Eli Lilly & Co (LLY)

Evan Seigerman

BMO Capital

CHF748.53→CHF885.36

Buy

92.47%

Upside

Reiterated

11/05/25

BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Chris Schott

J.P. Morgan

CHF845.12

Buy

83.72%

Upside

Reiterated

11/03/25

J.P. Morgan Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

CHF835.46

Buy

81.62%

Upside

Reiterated

10/31/25

Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Akash Tewari

Jefferies

CHF728.41→CHF785.56

Buy

70.77%

Upside

Reiterated

10/31/25

Eli Lilly & Co (LLY) Gets a Buy from Jefferies

Veda Pharmyne

TR | OpenAI - 4o

CHF730.83→CHF767.85

Buy

66.92%

Upside

Reiterated

10/31/25

AI Generated ArticleAI Generated Article

Courtney Breen

Bernstein

CHF885.36

Buy

92.47%

Upside

Reiterated

10/31/25

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Avantor (NYSE: AVTR)

Steve Scala

TD Cowen

CHF772.68

Buy

67.97%

Upside

Reiterated

10/30/25

Eli Lilly & Co (LLY) Gets a Buy from TD Cowen

David Risinger

Leerink Partners

CHF575.49

Hold

25.11%

Upside

Reiterated

10/23/25

Leerink Partners Keeps Their Hold Rating on Eli Lilly & Co (LLY)

Asad Haider

Goldman Sachs

CHF705.07→CHF707.49

Buy

53.80%

Upside

Reiterated

10/20/25

Eli Lilly & Co: Strategic Positioning and Clinical Advancements Drive Buy Rating

Seamus Fernandez

Guggenheim

CHF763.02

Buy

65.87%

Upside

Reiterated

10/15/25

Guggenheim Remains a Buy on Eli Lilly & Co (LLY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

1 Month

xxx

Success Rate

31/42 ratings generated profit

Average Return

+4.48%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.81% of your transactions generating a profit, with an average return of +4.48% per trade.

3 Months

xxx

Success Rate

31/42 ratings generated profit

Average Return

+10.80%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.81% of your transactions generating a profit, with an average return of +10.80% per trade.

1 Year

Geoff MeachamCiti

Success Rate

39/42 ratings generated profit

Average Return

+35.64%

reiterated a buy rating 5 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +35.64% per trade.

2 Years

xxx

Success Rate

41/42 ratings generated profit

Average Return

+60.59%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 97.62% of your transactions generating a profit, with an average return of +60.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q1G Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0Q1G has received 56 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 0Q1G average Analyst price target in the past 3 months is 791.13.

Each month's total comprises the sum of three months' worth of ratings.

0Q1G Financial Forecast

0Q1G Earnings Forecast

Next quarter’s earnings estimate for 0Q1G is CHF5.72 with a range of CHF5.37 to CHF7.08. The previous quarter’s EPS was CHF5.66. 0Q1G beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.

0Q1G Sales Forecast

Next quarter’s sales forecast for 0Q1G is CHF14.19B with a range of CHF13.67B to CHF14.49B. The previous quarter’s sales results were CHF14.20B. 0Q1G beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0Q1G has Performed in-line its overall industry.

0Q1G Stock Forecast FAQ

What is GB:0Q1G’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 791.13.

What is GB:0Q1G’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 71.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly & Co a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 18 buy ratings, 3 hold ratings and 0 sell ratings.

What is Eli Lilly & Co’s share price target?

The average share price target for Eli Lilly & Co is 791.13. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF1,008.18 ,and the lowest forecast is CHF564.58. The average share price target represents 71.98% Increase from the current price of CHF460.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Eli Lilly & Co?

To buy shares of GB:0Q1G, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Eli Lilly & Co (0Q1G) Share Forecast & Price Target

0Q1G Analyst Ratings

0Q1G Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

0Q1G Analyst Recommendation Trends

0Q1G Financial Forecast

0Q1G Earnings Forecast

0Q1G Sales Forecast

0Q1G Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts